Turning Point Therapeutics

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, Turning Point Therapeutics sits in the upper quartile of US sponsors by registered trial count (#1,806 of 15,742 sponsors by registered trial count).

7 total trials 2 currently recruiting 1 completed early-phase tilt upper quartile by trial count

Turning Point Therapeutics: 7 sponsored US clinical trials, 2 recruiting.

Turning Point Therapeutics sponsors 7 registered US clinical trials on ClinicalTrials.gov, 2 of them currently recruiting, and 1 completed. 0 of these trials are in Phase 3-4 (later-stage) and 7 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Metastatic Solid Tumors, with 3 trials.

Upper-quartile sponsor footprint

Turning Point Therapeutics sits in the upper quartile of the sponsor corpus (#1,806 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.

Open and recent trials

7 total, page 1 of 1

RECRUITING Phase 1

A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations

NCT04094610
RECRUITING Phase 1

A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements

NCT03093116
ACTIVE NOT RECRUITING Phase 1

Study of TPX-0022 in Patients With Advanced NSCLC, Gastric Cancer or Solid Tumors Harboring Genetic Alterations in MET

NCT03993873
COMPLETED Phase 1

Study of Turning Point Therapeutics LM-302 in Patients With Advance Solid Tumors

NCT05001516
TERMINATED Phase 1

A Study of Repotrectinib in Combination With Other Anticancer Therapies for the Treatment of Subjects With KRAS-Mutant Solid Tumors

NCT05071183
TERMINATED Phase 1

A Study of TPX-0131, a Novel Oral ALK Tyrosine Kinase Inhibitor, in Patients With ALK+ Advanced or Metastatic NSCLC

NCT04849273
TERMINATED Phase 1

Study of TPX-0046, A RET/SRC Inhibitor in Adult Subjects With Advanced Solid Tumors Harboring RET Fusions or Mutations

NCT04161391

Phase Distribution

PhaseTrial count
Phase 1 7

Therapeutic Areas

Metastatic Solid Tumors 3
Locally Advanced Solid Tumors 2
MET Gene Alterations 1
Primary CNS Tumors 1
Lymphoma 1
Advanced Solid Tumor 1

What is open in the Turning Point Therapeutics pipeline

2 recruiting of 7 indexed (29% open); 1 completed (14%).

Phase mix: 0 late (III/IV) vs 7 early (I/II) (early-phase heavy).

Top condition: Metastatic Solid Tumors (3 trials), 5 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Turning Point Therapeutics: open-pipeline peers nationwide

Peers matched on 7 registered trials and 29% open enrollment, not the therapeutic-area sidebar.

Turning Point Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 0102030405060 0%10%20%30%40% Total trials Recruiting share Turning Point Therapeutics3M4Life Research89bioAbbott Diagnostics DivisionAlabama Physical Therapy & AcupunctureAlloSourceAlnylam PharmaceuticalsAnnovis Bio
Turning Point Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Turning Point Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 7 trials (± recruiting share)

Sponsors near 29% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Turning Point Therapeutics page

7 registered trials is a research-attention snapshot, not an endorsement of Turning Point Therapeutics or any single study.

  • 2 of Turning Point Therapeutics's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Metastatic Solid Tumors is the condition Turning Point Therapeutics studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Metastatic Solid Tumors trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Turning Point Therapeutics pipeline card: 7 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.